US · RMTI
Rockwell Medical, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Wixom, MI 48393
- Website
- rockwellmed.com
Price · as of 2024-12-31
$0.89
Market cap 35.49M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $74.43 | +8,279.87% |
| Intrinsic Value(DCF) | $0.83 | -6.55% |
| Graham-Dodd Method(GD) | $0.94 | +6.06% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $99.00 | $2,138.62 | $85.25 | $10.62 | $0.00 |
| 2011 | $98.67 | $5,372.08 | $0.00 | $0.00 | $118.40 |
| 2012 | $48.95 | $109.62 | $0.00 | $0.00 | $0.00 |
| 2013 | $155.21 | $81.01 | $0.00 | $0.00 | $0.00 |
| 2014 | $111.10 | $438.38 | $11.46 | $0.00 | $0.00 |
| 2015 | $73.26 | $1,436.06 | $8.82 | $0.00 | $0.00 |
| 2016 | $64.57 | $71.75 | $5.25 | $0.00 | $0.00 |
| 2017 | $68.86 | $54.98 | $0.00 | $0.00 | $0.00 |
| 2018 | $55.66 | $30.63 | $0.00 | $0.00 | $0.00 |
| 2019 | $39.27 | $22.19 | $0.00 | $0.00 | $0.00 |
| 2020 | $14.74 | $16.71 | $0.12 | $0.00 | $0.00 |
| 2021 | $3.85 | $10.69 | $0.00 | $0.00 | $0.00 |
| 2022 | $1.43 | $57.86 | $0.00 | $0.00 | $0.00 |
| 2023 | $1.52 | $33.39 | $0.00 | $0.00 | $0.00 |
| 2024 | $1.62 | $74.43 | $7.33 | $0.94 | $0.00 |
AI valuation
Our deep-learning model estimates Rockwell Medical, Inc.'s (RMTI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $74.43
- Current price
- $0.89
- AI upside
- +8,279.87%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.83
-6.55% upside
Graham-Dodd
$0.94
+6.06% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RMTI | Rockwell Medical, Inc. | $0.89 | 35.49M | +8,280% | -7% | +6% | — | -104.82 | 1.54 | 0.50 | 14.30 | — | 2.34 | 17.23% | 0.60% | -0.47% | -1.78% | 2.52% | -0.86% | 0.42 | 0.48 | 2.63 | 2.12 | -0.72 | -9300.00% | 2138.00% | -13291.00% | 6.34% | 0.30 | 13.21% | 0.00% | 0.00% | 13.08% | 69.49 | 13.24 | 0.42 | -6.06 |
| ATHE | Alterity Therapeutics Lim… | $3.44 | 58.29M | +500% | +3% | — | — | -6.79 | 1.95 | 15.18 | -2.87 | — | 1.95 | 97.66% | -267.96% | -223.35% | -43.23% | -905.76% | -37.23% | 0.00 | — | 12.98 | 12.62 | 2.26 | -6346.00% | 3532.00% | -920.00% | -13.87% | -3.24 | -711.67% | 0.00% | 0.00% | 24.86% | -2.88 | -3.67 | 7.73 | 6.97 |
| CPIX | Cumberland Pharmaceutical… | $4.92 | 73.59M | +2,442% | -39% | — | — | -13.82 | 3.92 | 2.37 | 505.27 | -304.09 | 22.58 | 82.61% | -16.99% | -17.11% | -24.71% | -23.24% | -8.24% | 0.90 | -10.62 | 1.15 | 0.94 | 14.30 | 455.00% | -426.00% | -11404.00% | -0.88% | -0.02 | -2.87% | 0.00% | 0.00% | 0.65% | -14.33 | -116.39 | 2.43 | 0.87 |
| EVAX | Evaxion Biotech A/S | $3.16 | 19.96M | +25,906% | -76% | — | — | -0.19 | -1.22 | 0.60 | -0.72 | — | -1.22 | 100.00% | -440.55% | -316.00% | 331.20% | -693.28% | -83.29% | -6.11 | -15.31 | 2.01 | 1.58 | -0.52 | -6975.00% | 448082.00% | -2721.00% | -641.54% | -2.96 | -654.36% | 0.00% | 0.00% | 11.80% | -0.48 | -0.55 | 2.11 | -16.41 |
| LIMN | Liminatus Pharma, Inc. Cl… | $0.25 | 7.86M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 21.87% | 87.68% | -79.23% | -0.32 | -21.04 | 0.09 | 0.09 | -1.57 | 16667.00% | — | -713.00% | — | -0.36 | 93.72% | — | 0.00% | — | — | — | — | — |
| MURA | Mural Oncology plc | $2.04 | 35.38M | — | — | — | — | -0.48 | 0.44 | — | 0.60 | — | 0.44 | 0.00% | — | — | -63.57% | -2282.87% | -54.55% | 0.06 | — | 5.84 | 5.51 | 0.86 | -3902.00% | — | -3493.00% | -209.58% | -4.91 | -2123.95% | 0.00% | 0.00% | 0.00% | 0.54 | 0.58 | — | -1.84 |
| NMTC | NeuroOne Medical Technolo… | $0.67 | 33.87M | +8,902% | +225,949% | — | — | -7.93 | 4.04 | 2.36 | -7.40 | — | 4.07 | 67.30% | -34.94% | -29.80% | -91.34% | -2161.45% | -44.63% | 0.04 | -12.65 | 4.44 | 3.40 | 2.09 | -8043.00% | 25035.00% | -7378.00% | -10.21% | -1.23 | -1492.81% | 0.00% | 0.00% | 18.29% | -5.27 | -7.63 | 1.84 | -4.87 |
| QNTM | Quantum BioPharma Ltd. | $3.55 | 13.64M | — | — | — | — | -0.35 | 0.46 | — | 0.08 | — | 0.80 | 0.00% | — | — | -120.69% | -212.74% | -86.23% | 0.07 | -339.16 | 1.80 | 1.65 | 0.36 | -5750.00% | — | -3649.00% | -130.92% | -1.03 | -90.66% | 0.00% | 0.00% | 52.41% | 0.07 | 0.16 | — | -16.34 |
| STRR | Star Equity Holdings, Inc… | $9.98 | 34.29M | +11,500% | +1,775,496% | — | +1,761% | -3.07 | 0.79 | 0.60 | -3.35 | -1.19 | 1.00 | 20.72% | -15.77% | -19.56% | -23.46% | -32.46% | -18.39% | 0.03 | — | 3.58 | 3.31 | 3.31 | 25766.00% | -6693.00% | -50185.00% | -25.05% | -0.46 | -31.00% | 6.36% | -19.50% | 7.23% | -1.92 | -2.01 | 0.30 | -8.72 |
| TLPH | Talphera, Inc. | $0.91 | 18.7M | +3,728% | — | — | — | -1.09 | 1.78 | — | -0.78 | — | 1.78 | 0.00% | — | — | -117.65% | -293.62% | -67.32% | 0.82 | -38.71 | 3.56 | 3.35 | 0.15 | -6124.00% | -10000.00% | -2790.00% | -89.22% | -4.79 | -244.16% | 0.00% | 0.00% | 0.00% | -0.78 | -0.94 | — | -36.58 |
About Rockwell Medical, Inc.
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
- CEO
- Mark Strobeck
- Employees
- 244
- Beta
- 1.69
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.83 ÷ $0.89) − 1 = -6.55% (DCF, example).